Research Scientist Molecular Biology - Antibody Discovery KC055 :
Cambridge, United Kingdom
Kymab is a rapidly expanding biopharmaceutical company based in Cambridge,
UK and engaged in the discovery and development of human monoclonal antibody
therapeutics using its own proprietary transgenic mouse discovery platform.
Kymab just announced the completion of a $90-million ‘Series B’ equity
financing with several investors including The Wellcome Trust and the Bill and
Melinda Gates Foundation.
No comments:
Post a Comment